- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2013
- Public Summary Document (PSD) March 2013 PBAC Meeting - PDF
Ranibizumab – March 2013
Ranibizumab, solution for intravitreal injection, 2-3 mg in 0-23 mL, Lucentis®
Last updated
8 November 2023